Great comment in your SA article BKC. I agree, the potential for BET inhibitors in anti-inflammatory conditions including, but not limited to, rheumatoid arthritis and multiple sclerosis is huge. And Resverlogix is in such a unique position as the only company with a BD2-specific BET inhibitor in clinical trials. And furthermore, RVX-208 is already in Phase 3 trials. So any other company that develops a BD2-specific BET inhibitor will have to start all the way back in Phase 1. All the other companies with BET inhibitors in trials are the reversible pan-inhibitors. We've also heard comments here and there from Zenith and Resverlogix about their compound libraries and how they have several next-generation BET inhibitors that are BD-1 or BD-2 selective, with some being reversible others being covalent inhibitors. Pan-inhibitors may have their place in the clinic for certain terminal cancers, for example, and Zenith's covalent pan inhibitor(s) that are pre-clinical right now may prove to be superior to the reversible ones. But in my opinion, the future really is in these bromodomain selective BET inhibitors, which are more suitable to treating chronic inflammatory conditions as opposed to the acute terminal cancers.

Best regards,

BearDownAZ